Jul 9, 2021
Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, is increasing its focus and research activities in Europe. The company announced that it is working with several academic and clinical research organizations as part of those efforts, which include the transfer of its intellectual property assets to its recently formed wholly owned Ireland subsidiary. According to the announcement, Cybin will also continue building its IP portfolio of novel psychedelic compounds, delivery platforms and methods of use in psychiatric indications. The company noted that its growing portfolio of intellectual property includes 12 patent filings and four active drug programs featuring Cybin’s proprietary novel psychedelic compounds and focusing on three mental health indications: major depressive disorder, alcohol use disorder and anxiety disorders. In addition, the company has most recently filed an international patent application aimed at potentially obtaining patent coverage in 153 countries; the announcement also noted that the company has completed 51 preclinical studies designed to support progression of its novel molecules into clinical studies in early 2022.
In addition, Cybin has announced that its CEO Doug Drysdale will participate in a panel discussion at the Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit on July 13, 2021. The panel, “Emerging Psychedelic Therapies in the Field of Neuropsychiatry,” is slated to begin at 4:15 p.m. Eastern Time on the day of the event.
To view the full press releases, visit https://ibn.fm/rYThp and https://ibn.fm/Wv8Ec
About Cybin Inc.
Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.
Follow along as we bring you the latest live news updates from Australia and around the world.
NVIDIA shares fell after the CEO’s admission prompted a board investigation, raising questions about his future at the company he co-founded.
A leading union has criticised the move, saying it was told by Qantas earlier in the year there was “no plan” to offshore any jobs.
Jensen Huang’s liaison with an alleged Chinese spy could cost Nvidia billions, set America’s AI sector back in its arms race with China, and embroil the US president.
The charges against the employee of a company specialising in employing Indigenous workers will raise fresh questions about the government’s social procurement policy.
Qantas is set to outsource about 850 head office jobs after the company signed a multi-year deal with technology company Accenture.
The rumoured change could see a single button handle camera access, app launches and shortcuts.
Police have been stationed at several aged care homes across the city following a drive-by shooting at one and credible threats against a former property tycoon.
Retailers are being warned not to mislead shoppers into thinking they’re getting more of a deal than they actually are during Black Friday sales.
The commission will today call its first witnesses as it examines the controversial level crossing removal project on Melbourne’s fringe.
More than 80 Xiaomi, Redmi, and Poco phones and tablets are scheduled to receive the update.
Freezers in dozens of stores across at least 11 countries were cranked up remotely, in a hack that cost less than $10. It should worry Australians.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.